Technology, Healthcare Dec 06, 2021 03:39 PM (GMT+8) · EqualOcean
Financial Associated Press, Dec. 6 - Hengrui pharmaceutical announced that famitinib malate capsule, carrizumab for injection and shr-1802 for injection have obtained the notice of approval for drug clinical trial. On the same day, it was announced that the main end point results of the phase III clinical trial of shr8554 injection (shr8554-301) developed by the company and its subsidiaries reached the pre-set excellence standard. The results show that shr8554 injection can effectively treat moderate and severe pain after abdominal surgery and significantly improve the subjects' satisfaction with analgesic treatment.

This text is a result of machine translation.

Related companies：